<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-523" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sweet Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vashisht</surname>
            <given-names>Priyanka</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hearth Holmes</surname>
            <given-names>Michelene P.</given-names>
          </name>
          <aff>UNMC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priyanka Vashisht declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michelene Hearth Holmes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-523.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a rare condition characterized by the sudden onset of tender erythematous plaques or nodules, often accompanied by fever, arthralgia, and systemic symptoms such as headaches. Although the diagnosis is primarily based on clinical presentation, histological examination of the lesions reveals a neutrophilic infiltrate, which is crucial for confirming the diagnosis. Clinicians must be vigilant for atypical presentations, especially in patients with underlying conditions like myelodysplastic syndrome, where the infiltrate may present with atypical mononuclear cells instead of neutrophils. Effective management primarily involves systemic corticosteroids to alleviate symptoms and prevent complications.</p>
        <p>Participants in this course develop a deeper understanding of the clinical features, evaluation, and management strategies for Sweet syndrome. The course highlights the importance of recognizing atypical presentations and associations with hematologic malignancies. By fostering collaboration among dermatologists, hematologists, and primary care clinicians, the course emphasizes an interprofessional team approach to enhance patient care. This collaboration is essential for accurate diagnosis, timely management, and improved patient outcomes, ensuring that all aspects of a patient's health are considered in the treatment plan.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical signs and symptoms of Sweet syndrome, including acute-onset tender plaques, fever, and associated systemic symptoms.</p></list-item><list-item><p>Differentiate Sweet syndrome from other dermatological conditions with similar presentations, such as erythema nodosum and other neutrophilic dermatoses.</p></list-item><list-item><p>Screen patients with Sweet syndrome for underlying hematologic malignancies, particularly in cases with atypical clinical features or refractory symptoms.</p></list-item><list-item><p>Identify modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by Sweet syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=523&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=523">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-523.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sweet syndrome, first described in 1964 by Robert Douglas Sweet, is an acute febrile neutrophilic dermatosis.<xref ref-type="bibr" rid="article-523.r1">[1]</xref> Neutrophilic dermatoses consist of a group of noninfectious disorders that are characterized by neutrophilic infiltration of the skin (epidermis, dermis, or hypodermis) with or without true vasculitis. Neutrophilic dermatoses can be idiopathic or secondary to an underlying disorder, localized or generalized, and may or may not have extracutaneous manifestations. Sweet syndrome belongs to the nonvasculitic group of neutrophilic dermatosis disorders, with others including pyoderma gangrenosum, pustular psoriasis, reactive arthritis (Keratoderma blennorrhagicum), Bowed-associated dermatosis-arthritis syndrome, rheumatoid neutrophilic dermatosis, Behcet disease, acne fulminans, familial Mediterranean fever, and SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteomyelitis).</p>
        <p>Sweet syndrome characteristically demonstrates the sudden onset of well-defined tender plaques or nodules accompanied by&#x000a0;fever, arthralgias, ocular inflammation, headaches, and, rarely, oral or genital lesions.<xref ref-type="bibr" rid="article-523.r2">[2]</xref><xref ref-type="bibr" rid="article-523.r3">[3]</xref><xref ref-type="bibr" rid="article-523.r4">[4]</xref>&#x000a0;This condition may also be associated with other extracutaneous systemic manifestations, which are, however, rare.&#x000a0;The goal of pharmacotherapy in acute febrile neutrophilic dermatosis (eg, Sweet syndrome) is to reduce morbidity and complications. The best first-line option is systemic or topical corticosteroids if the lesions are limited. If corticosteroids are contraindicated, anti-inflammatory medications such as colchicine or dapsone are available options.</p>
      </sec>
      <sec id="article-523.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Sweet syndrome may be idiopathic, which is most common, or may be associated with an underlying condition.<xref ref-type="bibr" rid="article-523.r5">[5]</xref><xref ref-type="bibr" rid="article-523.r6">[6]</xref>&#x000a0;Several malignancies have reported correlations with Sweet syndrome, including myeloproliferative disorders (myelodysplasia, acute myelogenous leukemia, chronic myelogenous leukemia, multiple myeloma, monoclonal gammopathy, lymphoma, and rarely with solid tumors. Sweet syndrome may occur before, at the time of, or after the diagnosis of malignancy. When associated with malignancy, this condition is more likely to be associated with older age of onset and cytopenias. Pathological features with the histiocytoid sweet syndrome are more likely to be associated with malignancy, especially myelodysplastic syndrome.</p>
        <p>Sweet syndrome can also occur in association with several inflammatory and autoimmune diseases. These include inflammatory bowel disease (ulcerative colitis or Crohn disease), rheumatoid arthritis, systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, Behcet disease,&#x000a0;and dermatomyositis.<xref ref-type="bibr" rid="article-523.r7">[7]</xref>&#x000a0;Post-infectious Sweet syndrome has been described 1&#x000a0;to 3 weeks after upper respiratory and gastrointestinal infections. Association with other infections such as human immunodeficiency virus, viral hepatitis, tuberculosis, and there have been some reports of chlamydia infection.</p>
        <p>Drug-induced Sweet syndrome has been a well-known entity, with several drugs reported to cause Sweet syndrome. Granulocyte colony-stimulating factor is the most common drug, while several others, including antibiotics (minocycline, nitrofurantoin, trimethoprim-sulfamethoxazole, norfloxacin, ofloxacin), antihypertensives (hydralazine, furosemide), nonsteroidal anti-inflammatory drugs (diclofenac, celecoxib), immunosuppressives (azathioprine), antiepileptics (carbamazepine, diazepam), anti-cancer (bortezomib, imatinib mesylate, ipilimumab, lenalidomide, topotecan, vemurafenib), antipsychotics (clozapine), and antithyroid (propylthiouracil). Sweet syndrome, in these cases, occurs after exposure as well as re-exposure to the responsible drug and resolves with or without corticosteroids after the withdrawal of the drug. Pregnancy carries correlations with the development of Sweet syndrome in about 2% of cases. The prognosis is favorable, with spontaneous resolution after delivery and no infant or maternal morbidity or mortality.<xref ref-type="bibr" rid="article-523.r8">[8]</xref></p>
      </sec>
      <sec id="article-523.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Sweet syndrome has a predilection in women with a woman-to-man ratio of 4&#x000a0;to 1. The typical age of onset is between 30 and 60, although cases have been reported in the pediatric and elderly populations as well. There has been no observed racial predilection.</p>
      </sec>
      <sec id="article-523.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenesis of Sweet syndrome is not known. Some genetic factors such as HLA-B54 in the Japanese population,&#x000a0;<italic toggle="yes">MEFV</italic> gene mutation in familial Mediterranean fever patients,&#x000a0;and chromosome 3q abnormalities&#x000a0;have been observed in patients with Sweet syndrome.<xref ref-type="bibr" rid="article-523.r9">[9]</xref><xref ref-type="bibr" rid="article-523.r10">[10]</xref><xref ref-type="bibr" rid="article-523.r11">[11]</xref><xref ref-type="bibr" rid="article-523.r12">[12]</xref>&#x000a0;Theories regarding the pathogenesis of Sweet syndrome include hypersensitivity to eliciting bacterial, viral, or tumor antigens that may trigger neutrophil activation and infiltration, leading to Sweet syndrome. Another theory suggests the role of cytokines and chemokines such as&#x000a0;granulocyte colony-stimulating factor,&#x000a0;granulocyte-macrophage colony-stimulating factor,&#x000a0;interleukin-1, and interferon-gamma with a higher level of these cytokines reported in patients with Sweet syndrome.<xref ref-type="bibr" rid="article-523.r13">[13]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30247226">[14]</ext-link>&#x000a0;Studies for circulating immune complexes, complement activation, and tissue-bound immunoglobulins have been negative and not shown to be pathognomic in Sweet syndrome.</p>
      </sec>
      <sec id="article-523.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologic findings are a hallmark of Sweet syndrome, and typical histopathological features are a requirement for the diagnosis of Sweet syndrome. The classic histopathologic pattern of acute febrile neutrophilic dermatosis (Sweet syndrome) consists of a diffuse dense neutrophilic infiltrate in the reticular dermis. Leukocytoclastic nuclear debris presents interstitially, and papillary dermal edema is common. True vasculitic changes usually are absent, although subtle vasculitic changes may occur. Eosinophils and lymphocytes may be present, but neutrophils predominate.&#x000a0;The epidermis typically is spared, although spongiosis and subcorneal pustule formation may be present.</p>
        <p>Direct immunofluorescence testing is not contributory. In rare instances, the inflammation may extend to involve the subcutis. In most instances, cases with subcutaneous involvement show extensive involvement of the reticular dermis. Histiocytoid Sweet syndrome has been described as a variant and includes histiocytoid cells, which are immature myeloid cells, commonly mistaken as histiocytes. The most important differential diagnosis for this variant is leukemia cutis.</p>
      </sec>
      <sec id="article-523.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>While the characteristic presentation is that of&#x000a0;an abrupt onset of multiple tender, erythematous plaques or nodules, several extracutaneous manifestations may occur.&#x000a0;</p>
        <p>
<bold>Various Manifestations</bold>
</p>
        <p>
<bold>Cutaneous manifestations</bold>
</p>
        <p>The lesions of Sweet syndrome have an abrupt onset of tender erythematous plaques or nodules in varying sizes in an asymmetric distribution. Pustular, vesicular, bullous, and targetoid lesions can present. Lesions are most commonly seen on the upper extremities, but they can also be present on the face, neck, chest, back, and lower extremities. Oral or genital lesions are rare, with rare cases of oral ulcers reported, especially in association with hematological malignancies. Bullous lesions, which are more commonly associated with a hematological malignancy, may ulcerate, mimicking pyoderma gangrenosum. Subcutaneous involvement of the fat in Sweet syndrome leads to tender nodules that can mimic erythema nodosum. A positive pathergy test, as seen in Behcet disease, can also be seen in Sweet syndrome.</p>
        <p>
<bold>Constitutional symptoms</bold>
</p>
        <p>Fever is almost always present, especially in drug-induced Sweet syndrome, although it may be absent in 10% to 20% of cases of Sweet syndrome secondary to other etiologies. Arthralgia, myalgia, fatigue, malaise, and headache are other common constitutional symptoms seen in Sweet syndrome.</p>
        <p>
<bold>Extracutaneous manifestations</bold>
</p>
        <p>Joint involvement is common and may occur in 30% to 60% of cases. Arthralgias and non-erosive inflammatory arthritis have been reported.&#x000a0;Ocular inflammation, especially conjunctivitis, is also commonly seen. Other ophthalmologic manifestations may include episcleritis, scleritis, keratitis (including peripheral ulcerative keratitis), uveitis, and choroiditis.<xref ref-type="bibr" rid="article-523.r14">[15]</xref>&#x000a0;Reports exist of cases of Sweet syndrome&#x000a0;with other systemic involvement, including neutrophilic infiltration leading to myocarditis, multifocal sterile osteomyelitis, alveolitis, pleural effusions, and aseptic meningitis.</p>
        <p>
<bold>Diagnostic&#x000a0;Criteria</bold>
</p>
        <p>There are proposals for other clinical diagnostic criteria.<xref ref-type="bibr" rid="article-523.r15">[16]</xref>&#x000a0;These have undergone revision, and the revised criteria include&#x000a0;2 significant findings, which are the presence of (1) sudden onset eruption of tender, painful plaques or nodules and (2) neutrophilic infiltrate in the dermis without vasculitis. Both must be present to establish a diagnosis of Sweet syndrome. For diagnostic confirmation of Sweet syndrome, at least 2 minor clinical features should be present.</p>
        <p>These features may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fever &#x0003e;38 &#x000ba;C</p>
          </list-item>
          <list-item>
            <p>Illness preceded by an upper respiratory or gastrointestinal infection, or associated with an underlying typical inflammatory disorder, malignancy, or pregnancy</p>
          </list-item>
          <list-item>
            <p>Elevated white cell count with neutrophil predominance and elevated inflammatory markers</p>
          </list-item>
          <list-item>
            <p>Positive response to corticosteroids</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-523.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory findings in patients with Sweet syndrome include elevated markers of inflammation, including erythrocyte sedimentation rate and C-reactive protein, peripheral leukocytosis, and neutrophilia. Biopsy findings of dense can support the diagnosis of infiltrates in the superficial dermis composed primarily of polymorphonucleocytes and marked edema of the dermal papillae. Lymphocytes may also be present in the inflammatory infiltrate.&#x000a0;</p>
        <p>Besides the laboratory evaluation to aid the diagnosis of Sweet syndrome, workup shall include determining the underlying cause if present, especially malignancies. Complete blood counts with findings of cytopenias, constitutional symptoms including weight loss, lymphadenopathy, and absence of other typically-associated conditions, raise the suspicion of malignancy. Age-appropriate cancer screening, including colonoscopy, mammogram, and Papanicolaou&#x000a0;smears, should be pursued.</p>
        <p>Screening for testicular and prostate cancer in men and pelvic ultrasound in women should also be considerations for diagnostic workups. Computed tomography scans of the chest, abdomen, and pelvis are also options. Besides malignancy workup, a pregnancy test is necessary for women of childbearing age with Sweet syndrome. Sweet syndrome is usually not an initial presenting feature of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, or Behcet disease, and the clinician should pursue diagnostic evaluation for these conditions if other typical clinical findings create suspicion for their presence.</p>
      </sec>
      <sec id="article-523.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In the absence of associated malignancy or inflammatory bowel disease, Sweet syndrome is usually highly steroid-responsive and self-limiting. A 2 to 4-week tapering course of oral prednisone starting at a daily dose of 40 mg to 60 mg is usually effective. Intralesional corticosteroid injections and topical corticosteroids can also be used, especially in localized Sweet syndrome. In cases of recurrence of disease after corticosteroid tapering, several steroid-sparing agents have reportedly shown efficacy, including potassium iodide, colchicine, dapsone, isotretinoin, methotrexate, doxycycline, indomethacin, chlorambucil, and cyclosporine.<xref ref-type="bibr" rid="article-523.r16">[17]</xref><xref ref-type="bibr" rid="article-523.r8">[8]</xref><xref ref-type="bibr" rid="article-523.r17">[18]</xref></p>
      </sec>
      <sec id="article-523.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The primary differential diagnosis of Sweet syndrome is infections given the presence of fever, leukocytosis, neutrophilia, elevated inflammatory markers, and neutrophil-dense infiltrates. Bacterial, fungal, and mycobacterial infections all merit consideration, and the clinician must rule these out. The cutaneous lesions of Sweet syndrome may mimic several other conditions, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Cellulitis</p>
          </list-item>
          <list-item>
            <p>Behcets disease</p>
          </list-item>
          <list-item>
            <p>Herpes simplex</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity drug reaction</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme</p>
          </list-item>
          <list-item>
            <p>Erythema nodosum</p>
          </list-item>
          <list-item>
            <p>Pyoderma gangrenosum</p>
          </list-item>
        </list>
        <p>Other diagnoses in the differential include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Leukocytoclastic vasculitis</p>
          </list-item>
          <list-item>
            <p>Leukemia cutis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-523.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most cases resolve, although some persist indefinitely and can cause chronic pain and skin breakdown. Because this condition can be associated with other diseases, including malignancy, the prognosis varies depending on the underlying cause. Recurrence may occur in up to 50% of patients, usually in cases associated with an underlying inflammatory disease or hematologic malignancy.</p>
      </sec>
      <sec id="article-523.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Generally, with timely diagnosis and appropriate treatment, the lesions of Sweet syndrome resolve without scarring.</p>
      </sec>
      <sec id="article-523.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Sweet syndrome can present typically and atypically, and the diagnosis can be challenging. A biopsy is always necessary to confirm the diagnosis. Being mindful of the association with hematologic malignancy is essential. Patients with an underlying myelodysplastic syndrome may have the classical cutaneous lesions of Sweet syndrome but with lymphocytic, infiltrate, and atypical mononuclear infiltrate rather than neutrophils (see <bold>Image.&#x000a0;</bold>Underlying Myelodysplastic Syndrome).</p>
        <p>In some patients with classical Sweet syndrome, the signs and symptoms of this condition may spontaneously resolve without any form of medical intervention. However, the lesions often persist for many weeks or months in others. Successful management of any malignancy results in clearing the related dermatosis in patients with malignancy-associated Sweet syndrome. Similarly, spontaneous improvement and subsequent resolution of the syndrome typically follow discontinuation of the associated medication in patients with drug-induced Sweet syndrome.</p>
      </sec>
      <sec id="article-523.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sweet syndrome is a rare disorder of the skin. However, patients may usually present to the primary care clinician with abrupt onset of tender plaques or nodules, fever, arthralgias, ophthalmologic manifestations, headaches, and, rarely, oral or genital lesions. The role of dermatologists and pathologists is crucial in confirming the diagnosis. The involvement of other subspecialists, including an oncologist, rheumatologist, gastroenterologist, or infectious disease specialist, may be necessary if an underlying associated condition is present.&#x000a0;</p>
        <p>The goal of pharmacotherapy in acute febrile neutrophilic dermatosis is to reduce morbidity and complications. The best first-line option is systemic or topical corticosteroids if the lesions are limited. If corticosteroids are contraindicated, anti-inflammatory or immunosuppressive medications&#x000a0;may be options. The&#x000a0;healthcare team can ensure patient compliance, while a pharmacist can help to ensure avoidance of drug interactions. Recommendations include close monitoring and follow-up of the patient.</p>
      </sec>
      <sec id="article-523.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=523&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=523">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/sweet-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=523">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/523/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=523">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-523.s16">
        <fig id="article-523.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Underlying Myelodysplastic Syndrome. This image shows a patient in the intensive care unit with underlying myelodysplastic syndrome with multiple tender papules and plaques, including lesions with a targetoid and pseudovesicular appearance. Contributed by S Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sweet__syndrome__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-523.s17">
        <title>References</title>
        <ref id="article-523.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SWEET</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.</article-title>
            <source>Br J Dermatol</source>
            <year>1964</year>
            <season>Aug-Sep</season>
            <volume>76</volume>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">14201182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Siddappa Malleshappa</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Pasupula</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Duke</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shaaban</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bullous Variant of Sweet's Syndrome as a Consequence of Radioiodine Contrast Exposure.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Oct</month>
            <day>24</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>e3490</fpage>
            <pub-id pub-id-type="pmid">30648032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vettakkara</surname>
                <given-names>KMN</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baitha</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jorwal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soneja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Not so sweet; severe Sweet's syndrome presenting as SIRS and pleural effusion.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>1584</fpage>
            <page-range>1584-1587</page-range>
            <pub-id pub-id-type="pmid">30613566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens G</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yutronic H</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pizarro O</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Velozo P</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sweet Syndrome in Pediatrics. A case report.</article-title>
            <source>Rev Chil Pediatr</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>511</fpage>
            <page-range>511-515</page-range>
            <pub-id pub-id-type="pmid">30571826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azerad</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Drowart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewalle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Efira</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report].</article-title>
            <source>Rev Med Interne</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>258</fpage>
            <page-range>258-261</page-range>
            <pub-id pub-id-type="pmid">30551891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arun Kumar</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Alghali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual consequence of azathioprine-induced treatment.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">30455717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Adil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quint</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Behcet Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">29262080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corbeddu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pilloni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinna</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rongioletti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Atzori</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Sweet's syndrome in pregnancy.</article-title>
            <source>Dermatol Ther</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>e12619</fpage>
            <pub-id pub-id-type="pmid">30043469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanbe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome.</article-title>
            <source>Int J Dermatol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1079</fpage>
            <page-range>1079-80</page-range>
            <pub-id pub-id-type="pmid">20883277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Migita</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome in patients with MDS and MEFV mutations.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>12</day>
            <volume>372</volume>
            <issue>7</issue>
            <fpage>686</fpage>
            <page-range>686-8</page-range>
            <pub-id pub-id-type="pmid">25671271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Jankovi&#x00107;</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Strahinja</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome associated with paracentric inversion of chromosome 3q in a patient with multiple myeloma.</article-title>
            <source>Eur J Haematol</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-9</page-range>
            <pub-id pub-id-type="pmid">8856100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mijovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Medenica</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome associated with inversion of chromosome 3q in a patient with refractory anemia.</article-title>
            <source>Eur J Haematol</source>
            <year>1992</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-7</page-range>
            <pub-id pub-id-type="pmid">1446734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Franceschini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anemona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Passarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vaccarini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pupo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nasso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cantonetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Sweet's syndrome in a patient with multiple myeloma.</article-title>
            <source>Clin Case Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>1958</fpage>
            <page-range>1958-1960</page-range>
            <pub-id pub-id-type="pmid">30349706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belliveau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heathcote</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): new cases and review of the literature.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-26</page-range>
            <pub-id pub-id-type="pmid">18501268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria for Sweet's syndrome.</article-title>
            <source>Cutis</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-74</page-range>
            <pub-id pub-id-type="pmid">3514153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Babik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ortega-Loayza</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCalmont</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Demer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mansh</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hylwa</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">30383110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-523.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinser</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Panach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dominguez</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Malignancy-Associated Atypical Neutrophilic Dermatosis With Noninfectious Shock.</article-title>
            <source>Am J Med Sci</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>354</volume>
            <issue>6</issue>
            <fpage>626</fpage>
            <page-range>626-632</page-range>
            <pub-id pub-id-type="pmid">29208261</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
